• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


Prices delayed by at least 15 minutes | Print

Agios Pharmaceuticals (AGIO)

Common Shares
Sell: $33.18|Buy: $33.9|Change: 0.54 (1.64%)

This share can be held in a Dealing accountISALifetime ISAJISASIPP

Company profile

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Address

88 Sidney Street
Cambridge
MA
USA
02139

Telephone

+1 617 6498600

Website

https://www.agios.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Agios Pharmaceuticals Inc First Quarter Earnings Conference Call for 20252025-05-02T08:00:00
Agios Pharmaceuticals Inc First Quarter Earnings Results for 20252025-05-02T00:00:00
Agios Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20242025-02-14T08:00:00
Agios Pharmaceuticals Inc Fourth Quarter Earnings Results for 20242025-02-14T00:00:00
Agios Pharmaceuticals Inc Annual Report for 20242025-02-14T00:00:00
Agios Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20242024-11-01T08:00:00
Agios Pharmaceuticals Inc Third Quarter Earnings Results for 20242024-11-01T00:00:00
Agios Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20242024-08-02T08:00:00
Agios Pharmaceuticals Inc Second Quarter Earnings Results for 20242024-08-02T00:00:00
Agios Pharmaceuticals Inc Annual General Meeting for 20242024-06-13T09:00:00
Agios to Present at the BofA Securities 2024 Health Care Conference2024-05-16T11:40:00
Agios to Present at the RBC Capital Markets Global Healthcare Conference2024-05-14T08:00:00
Agios Pharmaceuticals Inc First Quarter Earnings Conference Call for 20242024-05-02T08:00:00
Agios Pharmaceuticals Inc First Quarter Earnings Result for 20242024-05-02T00:00:00

Previous key dates

NameKey Date
Agios to Present at the BofA Securities 2024 Health Care Conference2024-05-16T11:40:00
Agios to Present at the RBC Capital Markets Global Healthcare Conference2024-05-14T08:00:00
Agios Pharmaceuticals Inc First Quarter Earnings Conference Call for 20242024-05-02T08:00:00
Agios Pharmaceuticals Inc First Quarter Earnings Result for 20242024-05-02T00:00:00
Agios Pharmaceuticals Inc o present at the Leerink Partners Global Biopharma Conference2024-03-12T10:00:00
Leerink Partners Global Biopharma Conference2024-03-12T10:00:00
Td cowen 44th annual health care conference2024-03-04T14:10:00
Agios Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20232024-02-15T08:00:00
Agios Pharmaceuticals Inc Fourth Quarter Earnings Result for 20232024-02-15T00:00:00
Agios Pharmaceuticals Inc Annual Report for 20232024-02-15T00:00:00
ENERGIZE Phase 3 Topline Results2024-01-03T08:00:00
Agios IR Breakout at ASH 20232023-12-11T10:00:00
Agios Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20232023-11-02T08:00:00
Agios Pharmaceuticals Inc Third Quarter Earnings Result for 20232023-11-02T00:00:00
Agios Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20232023-08-03T08:00:00
Agios Pharmaceuticals Inc Second Quarter Earnings Result for 20232023-08-03T00:00:00
RISE UP Phase 2 Topline Results2023-06-26T08:00:00
Agios Pharmaceuticals Inc Annual General Meeting for 20232023-06-13T09:00:00
Agios Pharmaceuticals Inc First Quarter Earnings Conference Call for 20232023-05-04T08:00:00
Agios Pharmaceuticals Inc First Quarter Earnings Result for 20232023-05-04T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.